Metastatic Squamous Neck Cancer with Occult Primary: Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Metastatic squamous cell carcinoma of the cervical lymph nodes with occult primary — also termed 'cervical CUP (cancer of unknown primary)' — is a challenging oncological entity in which squamous cell carcinoma (SCC) is identified in one or more cervical lymph nodes but extensive diagnostic evaluation fails to identify a primary mucosal tumor site. It accounts for 2–4% of head and neck cancers and represents the most common histological type of CUP in the neck. The rising incidence of HPV-associated oropharyngeal cancer has fundamentally changed the biology and prognosis of this condition: 50–70% of cervical CUP in Western countries are HPV-16 positive (confirmed by p16 IHC and CISH), arising from occult tonsillar or base-of-tongue primaries too small to detect on conventional endoscopy or imaging. HPV-positive cervical CUP has significantly better prognosis (3-year OS 90–95%) than HPV-negative or EBV-negative cases (3-year OS 40–60%), mirroring the improved outcomes of HPV-associated oropharyngeal cancer. Distinguishing this entity from cervical lymphadenopathy due to benign causes or other malignancies (lymphoma, thyroid cancer, salivary gland carcinoma) is critical for appropriate treatment.

The majority of cervical CUP with SCC histology originate from the Waldeyer's ring (palatine tonsils, base of tongue, adenoids, nasopharynx) — lymphoid tissue-rich areas where small mucosal primaries may be concealed within crypts and not apparent on standard endoscopy. HPV-16 infection is the dominant causative factor in oropharyngeal-origin CUP — the same risk factors apply as for HPV-positive oropharyngeal cancer: multiple sexual partners, oral-genital contact, and immunosuppression. Epstein-Barr virus (EBV) is the etiological agent for nasopharyngeal carcinoma presenting as a cervical mass with occult or minimally symptomatic nasopharyngeal primary — common in patients of East Asian origin. Tobacco smoking and heavy alcohol use remain risk factors for HPV-negative squamous CUP arising from hypopharyngeal or laryngeal primaries obscured by poor visualization. Advanced age (>50 years), male sex, and white ethnicity are demographic risk factors. Immunosuppression (post-transplant, HIV) increases HPV-associated malignancy risk.

The typical presentation is a painless, enlarging unilateral cervical lymph node mass — most commonly in the level II (upper deep cervical) or level III (mid deep cervical) nodal chains. The node is usually >2 cm, firm, non-tender, and may feel fixed to adjacent structures in advanced disease. Bilateral neck involvement is less common. The absence of an obvious throat, mouth, or pharyngeal primary site lesion on initial examination is the defining feature. Some patients report ipsilateral sore throat, dysphagia, or referred otalgia that may provide a clue to a microscopic tonsillar or base-of-tongue primary. Anterior triangle nodes at levels I–III suggest an oropharyngeal, oral cavity, or hypopharyngeal origin; posterior triangle (level V) nodes suggest a nasopharyngeal or supraclavicular primary. Constitutional symptoms (fever, weight loss) may indicate lymphoma rather than SCC. Cystic neck nodes on CT or ultrasound strongly suggest HPV-associated oropharyngeal origin — a well-recognized clinical pitfall that can mimic a benign branchial cleft cyst.

The diagnostic algorithm aims to identify a primary tumor that may alter treatment planning. Step 1: FNA cytology of the neck node establishes SCC histology and obtains material for HPV testing (p16 IHC, HPV ISH) and EBV testing (EBER ISH). Step 2: PET-FDG CT is the most sensitive imaging modality for identifying occult primary sites and distant metastases — it detects a primary in 20–30% of cases where prior CT/MRI was negative. Step 3: Targeted biopsies with MRI head and neck (superior soft-tissue resolution) for mucosal mapping. Step 4: Panendoscopy with directed biopsies under general anaesthesia — ipsilateral (and often bilateral) palatine tonsillectomy is the key diagnostic manoeuvre, as up to 25% of occult oropharyngeal primaries are within tonsillar crypts. Transoral robotic surgery (TORS)-assisted base of tongue mucosectomy is increasingly used at specialist centers to identify tonsillar fossa or base-of-tongue primaries not seen endoscopically. Step 5: Nasopharyngoscopy with nasopharyngeal biopsy (and EBV serology) to exclude NPC. After all investigations, a primary tumor is still not identified in 15–25% of patients — these are true cervical CUP and are managed as per NCCN CUP guidelines with definitive locoregional treatment.

Treatment is guided by HPV/EBV status, nodal stage, and whether a primary site has been identified. When an oropharyngeal primary is identified after tonsillectomy or TORS mucosectomy, treatment follows oropharyngeal cancer protocols: definitive concurrent chemoradiation (cisplatin 100 mg/m² every 21 days or weekly cisplatin 40 mg/m² with IMRT) or surgery (TORS + neck dissection) ± adjuvant therapy based on pathological findings. For true cervical CUP (no primary identified after full workup): the treatment field encompasses the bilateral pharyngeal mucosal axis (nasopharynx, oropharynx, hypopharynx, larynx) and bilateral cervical lymph nodes plus the ipsilateral neck. Elective mucosal irradiation to the entire Waldeyer's ring reduces subsequent primary detection rates and may improve regional control. Ipsilateral neck dissection followed by adjuvant radiation is an alternative for N1–N2a disease. HPV-positive cervical CUP has excellent outcomes with definitive chemoradiation, with 3-year progression-free survival exceeding 85%. De-escalation clinical trials (ECOG-ACRIN 3311, PATHOS) are investigating reduced-intensity treatment for HPV-positive early-stage disease. Palliative systemic therapy with cisplatin/5-FU ± pembrolizumab follows KEYNOTE-048 data for recurrent/metastatic disease.

Prognosis for cervical squamous cell carcinoma with occult primary depends critically on HPV/p16 status and nodal stage. HPV-positive (p16+) cervical CUP has an excellent prognosis, reflecting its oropharyngeal origin: 3-year overall survival is 90–95% even with N2–N3 nodal disease treated with definitive chemoradiation, mirroring outcomes for known HPV-positive oropharyngeal cancer. HPV-negative cervical CUP (tobacco- and alcohol-related) has significantly worse prognosis: 3-year overall survival of 40–60%, similar to other HPV-negative HNSCC. EBV-positive CUP (nasopharyngeal origin) has an intermediate prognosis depending on stage, with 5-year survival of 60–80% for locally advanced disease treated with cisplatin-based chemoradiation. Key prognostic factors include p16/HPV status, EBV status, nodal stage (N1 vs N2 vs N3), extranodal extension, performance status, and response to chemoradiation. Patients whose primary site is eventually identified after tonsillectomy or TORS mucosectomy may be treated with smaller radiation fields and reduced doses in HPV-positive cases, improving functional outcomes without compromising cancer control. Surveillance post-treatment includes clinical examination and MRI/CT at 3-month intervals for 2 years, then every 6 months to 5 years. De-escalation clinical trials are actively exploring reduced-intensity treatment for HPV-positive disease to minimize late toxicity (xerostomia, dysphagia) while maintaining excellent survival rates.

HPV vaccination (Gardasil 9, targeting HPV 16/18) is the primary preventive intervention for HPV-associated occult oropharyngeal carcinomas presenting as cervical CUP — vaccination programs in adolescents are expected to reduce the incidence of HPV-positive oropharyngeal and cervical CUP in coming decades. Tobacco cessation and alcohol reduction lower the risk of HPV-negative squamous CUP arising from the oral cavity, larynx, and hypopharynx. There is no population-based screening strategy for cervical CUP. Patients with a significant smoking history or HPV risk factors should practice regular oral self-examination and report any persistent neck lump, sore throat, or dysphagia to their physician promptly. Health professionals should not attribute a persistent unexplained neck mass in an adult to a benign cause without appropriate investigation, regardless of age.

Any adult with a persistent cervical lymph node swelling lasting more than 3 weeks that does not have an obvious infective cause (e.g., acute tonsillitis, dental abscess) must be evaluated urgently by an ENT or head and neck surgeon. NICE NG12 mandates an urgent 2-week-wait referral for unexplained cervical lymphadenopathy in adults. A cystic neck mass in an adult over 40 should not be assumed to be a congenital branchial cyst — squamous carcinoma presenting as a cystic neck node is a common diagnostic pitfall. FNA should be the first investigative step, not open biopsy (which violates surgical oncology principles and can compromise subsequent neck dissection planes). Incisional biopsy of a cervical lymph node without prior FNA, imaging, and specialist assessment is inappropriate and may harm the patient.